Paul Willner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/275759/publications.pdf Version: 2024-02-01

119 papers	13,274 citations	47006 47 h-index	24982 109 g-index
121	121	121	8891
all docs	docs citations	times ranked	citing authors

DALLI WILLINED

#	Article	IF	CITATIONS
1	The effect on and experience of families with a member who has Intellectual and Developmental Disabilities of the COVID-19 pandemic in the UK: developing an investigation. International Journal of Developmental Disabilities, 2022, 68, 234-236.	2.0	66
2	Perspectives for therapy of treatmentâ€resistant depression. British Journal of Pharmacology, 2022, 179, 4181-4200.	5.4	30
3	Occupational stress, coping and wellbeing among registered psychologists working with people with intellectual disabilities during the COVID-19 pandemic in the United Kingdom. Journal of Intellectual and Developmental Disability, 2022, 47, 195-205.	1.6	6
4	Optogenetic stimulation of medial prefrontal cortex excites GABAergic cells in the nucleus accumbens and hippocampus of Wistar-Kyoto rats exposed to chronic mild stress. Psychopharmacology, 2022, 239, 2299-2307.	3.1	2
5	The experiences of mothers of children and young people with intellectual disabilities during the first COVIDâ€19 lockdown period. Journal of Applied Research in Intellectual Disabilities, 2021, 34, 1421-1430.	2.0	46
6	The Experiences of Carers of Adults With Intellectual Disabilities During the First <scp>COVID</scp> â€19 Lockdown Period. Journal of Policy and Practice in Intellectual Disabilities, 2021, 18, 254-262.	2.7	22
7	Insufficiency of ventral hippocampus to medial prefrontal cortex transmission explains antidepressant non-response. Journal of Psychopharmacology, 2021, 35, 1253-1264.	4.0	7
8	AMPA receptors mediate the pro-cognitive effects of electrical and optogenetic stimulation of the medial prefrontal cortex in antidepressant non-responsive Wistar–Kyoto rats. Journal of Psychopharmacology, 2020, 34, 1418-1430.	4.0	13
9	Effect of the COVIDâ€19 pandemic on the mental health of carers of people with intellectual disabilities. Journal of Applied Research in Intellectual Disabilities, 2020, 33, 1523-1533.	2.0	175
10	Genomic Screening of Wistar and Wistar-Kyoto Rats Exposed to Chronic Mild Stress and Deep Brain Stimulation of Prefrontal Cortex. Neuroscience, 2019, 423, 66-75.	2.3	11
11	The role of prefrontal cortex dopamine D2 and D3 receptors in the mechanism of action of venlafaxine and deep brain stimulation in animal models of treatment-responsive and treatment-resistant depression. Journal of Psychopharmacology, 2019, 33, 748-756.	4.0	18
12	Functional lateralization in the prefrontal cortex of dopaminergic modulation of memory consolidation. Behavioural Pharmacology, 2019, 30, 514-520.	1.7	7
13	Validation of chronic mild stress in the Wistar-Kyoto rat as an animal model of treatment-resistant depression. Behavioural Pharmacology, 2019, 30, 239-250.	1.7	53
14	Effects on brain-derived neurotrophic factor signalling of chronic mild stress, chronic risperidone and acute intracranial dopamine receptor challenges. Behavioural Pharmacology, 2018, 29, 537-542.	1.7	1
15	The UK Mental Capacity Act and consent to research participation: asking the right question. Journal of Medical Ethics, 2018, 44, 44-46.	1.8	0
16	The prevalence of mental health difficulties in a sample of prisoners in Trinidadian prisons referred for anger management. Journal of Forensic Practice, 2018, 20, 249-256.	0.5	2
17	Rapid antidepressant effects of deep brain stimulation of the pre-frontal cortex in an animal model of treatment-resistant depression. Journal of Psychopharmacology, 2018, 32, 1133-1140.	4.0	27
18	Sleep does not cause false memories on a story-based test of suggestibility. Consciousness and Cognition, 2017, 52, 39-46.	1.5	5

#	Article	IF	CITATIONS
19	Intellectual disability in a prison population with anger problems in Trinidad. Journal of Forensic Psychiatry and Psychology, 2017, 28, 513-524.	1.0	0
20	Antidepressant, anxiolytic and procognitive effects of subacute and chronic ketamine in the chronic mild stress model of depression. Behavioural Pharmacology, 2017, 28, 1-8.	1.7	49
21	Dopaminergic mechanisms in memory consolidation and antidepressant reversal of a chronic mild stress-induced cognitive impairment . Psychopharmacology, 2017, 234, 2571-2585.	3.1	31
22	Reliability of the chronic mild stress model of depression: A user survey. Neurobiology of Stress, 2017, 6, 68-77.	4.0	141
23	The chronic mild stress (CMS) model of depression: History, evaluation and usage. Neurobiology of Stress, 2017, 6, 78-93.	4.0	636
24	Cognitiveâ€behavioural therapy for heroin and cocaine use: Ecological momentary assessment of homework simplification and compliance. Psychology and Psychotherapy: Theory, Research and Practice, 2016, 89, 276-293.	2,5	13
25	Trauma-focussed cognitive-behaviour therapy for people with mild intellectual disabilities: outcomes of a pilot study. Advances in Mental Health and Intellectual Disabilities, 2016, 10, 299-310.	1.1	29
26	Assessment of Anger-Related Cognitions of People with Intellectual Disabilities. Behavioural and Cognitive Psychotherapy, 2016, 44, 580-600.	1.2	4
27	Antidepressant, anxiolytic and procognitive effects of rivastigmine and donepezil in the chronic mild stress model in rats. Psychopharmacology, 2016, 233, 1235-1243.	3.1	51
28	Treatment-resistant depression: are animal models of depression fit for purpose?. Psychopharmacology, 2015, 232, 3473-3495.	3.1	116
29	The neurobiology of aggression: implications for the pharmacotherapy of aggressive challenging behaviour by people with intellectual disabilities. Journal of Intellectual Disability Research, 2015, 59, 82-92.	2.0	29
30	Depression: from psychopathology to pathophysiology. Current Opinion in Neurobiology, 2015, 30, 24-30.	4.2	142
31	Effects of chronic mild stress on the development of drug dependence in rats. Behavioural Pharmacology, 2014, 25, 518-531.	1.7	11
32	Resistance to antidepressant drugs. Behavioural Pharmacology, 2014, 25, 352-371.	1.7	29
33	What do NHS staff learn from training on the Mental Capacity Act (2005)?. Legal and Criminological Psychology, 2013, 18, 83-101.	2.0	13
34	The neurobiology of depression and antidepressant action. Neuroscience and Biobehavioral Reviews, 2013, 37, 2331-2371.	6.1	386
35	Different Factors Influence Selfâ€Reports and Thirdâ€Party Reports of Anger by Adults with Intellectual Disabilities. Journal of Applied Research in Intellectual Disabilities, 2013, 26, 410-419.	2.0	15
36	Group-based cognitive–behavioural anger management for people with mild to moderate intellectual disabilities: cluster randomised controlled trial. British Journal of Psychiatry, 2013, 203, 288-296	2.8	94

#	Article	IF	CITATIONS
37	Animal Models for Psychiatric States. , 2013, , 1-8.		1
38	Anger management for people with mild to moderate learning disabilities: Study protocol for a multi-centre cluster randomized controlled trial of a manualized intervention delivered by day-service staff. Trials, 2011, 12, 36.	1.6	13
39	Anger management groups for adolescents: A mixed-methods study of efficacy and treatment preferences. Clinical Child Psychology and Psychiatry, 2011, 16, 33-52.	1.6	22
40	A visual aid to decision-making for people with intellectual disabilities. Research in Developmental Disabilities, 2011, 32, 37-46.	2.2	46
41	Knowledge of Mental Capacity Issues in Community Teams for Adults with Learning Disabilities. Journal of Applied Research in Intellectual Disabilities, 2011, 24, 159-171.	2.0	18
42	Knowledge of Advocacy Options within Services for People with Learning Disabilities. Journal of Applied Research in Intellectual Disabilities, 2011, 24, 274-279.	2.0	4
43	Coins and Costs: A Simple and Rapid Assessment of Basic Financial Knowledge. Journal of Applied Research in Intellectual Disabilities, 2011, 24, 285-289.	2.0	1
44	Assessment of capacity to participate in court proceedings: a selective critique and some recommendations. Psychology, Crime and Law, 2011, 17, 117-131.	1.0	3
45	What do newly appointed health staff know about the Mental Capacity Act (2005)?. Medicine, Science and the Law, 2011, 51, 97-101.	1.0	10
46	Performance in Temporal Discounting Tasks by People With Intellectual Disabilities Reveals Difficulties in Decision-Making and Impulse Control. American Journal on Intellectual and Developmental Disabilities, 2010, 115, 157-171.	1.6	41
47	Antipsychotic-Induced Movement Disorders. , 2010, , 115-115.		0
48	Area Under the Curve. , 2010, , 151-151.		1
49	Animal Models for Psychiatric States. , 2010, , 84-89.		1
50	Attribution Theory Applied to Helping Behaviour Towards People with Intellectual Disabilities Who Challenge. Journal of Applied Research in Intellectual Disabilities, 2008, 21, 150-155.	2.0	43
51	EPILOGUE: Translational Models for the 21st Century: Reminiscence, Reflections, and Some Recommendations. , 2008, , 457-473.		Ο
52	CBT for People with Intellectual Disabilities: Emerging Evidence, Cognitive Ability and IQ Effects. Behavioural and Cognitive Psychotherapy, 2008, 36, 723-733.	1.2	117
53	Cognitive behavioural therapy for people with learning disabilities: focus on anger. Advances in Mental Health and Learning Disabilities, 2007, 1, 14-21.	0.3	33
54	Generalization of Anger-Coping Skills from Day-Service to Residential Settings. Journal of Applied Research in Intellectual Disabilities, 2007, 20, 553-562.	2.0	27

#	Article	IF	CITATIONS
55	Interaction of Cognitive Distortions and Cognitive Deficits in the Formulation and Treatment of Obsessive-Compulsive Behaviours in a Woman with an Intellectual Disability. Journal of Applied Research in Intellectual Disabilities, 2006, 19, 67-73.	2.0	34
56	Readiness for Cognitive Therapy in People with Intellectual Disabilities. Journal of Applied Research in Intellectual Disabilities, 2006, 19, 5-16.	2.0	89
57	Animal Models of Depression. , 2006, , 223-292.		0
58	Excessive alcohol consumption and dependence on amphetamine are associated with parallel increases in subjective ratings of both †wanting' and †liking'. Addiction, 2005, 100, 1487-1495.	3.3	20
59	Dopaminergic mechanism of antidepressant action in depressed patients. Journal of Affective Disorders, 2005, 86, 37-45.	4.1	149
60	Suggestibility and salience in people with intellectual disabilities: An experimental critique of the Gudjonsson Suggestibility Scale. Journal of Forensic Psychiatry and Psychology, 2005, 16, 638-650.	1.0	17
61	Chronic Mild Stress (CMS) Revisited: Consistency and Behavioural-Neurobiological Concordance in the Effects of CMS. Neuropsychobiology, 2005, 52, 90-110.	1.9	1,378
62	Psychological Factors in Risk Assessment and Management of Inappropriate Sexual Behaviour by Men with Intellectual Disabilities. Journal of Applied Research in Intellectual Disabilities, 2004, 17, 285-297.	2.0	10
63	Brief cognitive therapy of nightmares and post-traumatic ruminations in a man with a learning disability. British Journal of Clinical Psychology, 2004, 43, 459-464.	3.5	25
64	Self-report measures of defeat and entrapment during a brief depressive mood induction. Cognition and Emotion, 2002, 16, 629-642.	2.0	19
65	A Randomized Controlled Trial of the Efficacy of a Cognitive-Behavioural Anger Management Group for Clients with Learning Disabilities. Journal of Applied Research in Intellectual Disabilities, 2002, 15, 224-235.	2.0	147
66	A view through the gateway: expectancies as a possible pathway from alcohol to cannabis. Addiction, 2001, 96, 691-703.	3.3	46
67	Mediation of depression by perceptions of defeat and entrapment in high-stress mothers. The British Journal of Medical Psychology, 2001, 74, 473-485.	0.5	40
68	Further validation and development of a screening instrument for the assessment of substance misuse in adolescents. Addiction, 2000, 95, 1691-1698.	3.3	21
69	Alcohol sales to underage adolescents: an unobtrusive observational field study and evaluation of a police intervention. Addiction, 2000, 95, 1373-1388.	3.3	78
70	The mesolimbic dopamine system as a target for rapid antidepressant action. International Clinical Psychopharmacology, 1997, 12, S7-S14.	1.7	175
71	Anti-anhedonic actions of the novel serotonergic agent flibanserin, a potential rapidly-acting antidepressant. European Journal of Pharmacology, 1997, 340, 121-132.	3.5	61
72	Diurnal Variation in the Effect of Chronic Mild Stress on Sucrose Intake and Preference. Physiology and Behavior, 1997, 62, 421-426.	2.1	95

#	Article	IF	CITATIONS
73	Changes in sleep architecture following chronic mild stress. Biological Psychiatry, 1997, 41, 419-427.	1.3	156
74	Validity, reliability and utility of the chronic mild stress model of depression: a 10-year review and evaluation. Psychopharmacology, 1997, 134, 319-329.	3.1	1,607
75	The chronic mild stress procedure as an animal model of depression: valid, reasonably reliable, and useful. Psychopharmacology, 1997, 134, 371-377.	3.1	67
76	Decreased hedonic responsiveness following chronic mild stress is not secondary to loss of body weight. Physiology and Behavior, 1996, 60, 129-134.	2.1	173
77	Pharmacological validation of the chronic mild stress model of depression. European Journal of Pharmacology, 1996, 296, 129-136.	3.5	178
78	Attenuation of sucrose consumption in mice by chronic mild stress and its restoration by imipramine. Psychopharmacology, 1995, 117, 453-457.	3.1	207
79	Loss of social status: preliminary evaluation of a novel animal model of depression. Journal of Psychopharmacology, 1995, 9, 207-213.	4.0	58
80	Effects of imipramine on serotonergic and beta-adrenergic receptor binding in a realistic animal model of depression. Psychopharmacology, 1994, 114, 309-314.	3.1	103
81	Parallel changes in dopamine D2 receptor binding in limbic forebrain associated with chronic mild stress-induced anhedonia and its reversal by imipramine. Psychopharmacology, 1994, 115, 441-446.	3.1	188
82	Reversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexole. Psychopharmacology, 1994, 115, 454-462.	3.1	119
83	Stereospecific reversal of stress-induced anhedonia by mianserin and its (+)-enantiomer. Psychopharmacology, 1994, 116, 523-528.	3.1	46
84	Effects of chronic mild stress on performance in behavioural tests relevant to anxiety and depression. Physiology and Behavior, 1994, 56, 861-867.	2.1	293
85	Subsensitivity to rewarding and locomotor stimulant effects of a dopamine agonist following chronic mild stress. Psychopharmacology, 1993, 110, 152-158.	3.1	78
86	Behavioural sensitization to a dopamine agonist is associated with reversal of stress-induced anhedonia. Psychopharmacology, 1993, 110, 159-164.	3.1	42
87	Attenuation of place preference conditioning but not place aversion conditioning by chronic mild stress. Journal of Psychopharmacology, 1992, 6, 352-356.	4.0	82
88	Suppression of sucrose drinking by chronic mild unpredictable stress: A methodological analysis. Neuroscience and Biobehavioral Reviews, 1992, 16, 507-517.	6.1	223
89	Decreased reactivity to sweetness following chronic exposure to mild unpredictable stress or acute administration of pimozide. Neuroscience and Biobehavioral Reviews, 1992, 16, 519-524.	6.1	42
90	Chronic mild stress-induced anhedonia: A realistic animal model of depression. Neuroscience and Biobehavioral Reviews, 1992, 16, 525-534.	6.1	1,051

#	Article	IF	CITATIONS
91	Reversal of stress-induced anhedonia by the atypical antidepressants, fluoxetine and maprotiline. Psychopharmacology, 1992, 109, 433-438.	3.1	214
92	Animal models as simulations of depression. Trends in Pharmacological Sciences, 1991, 12, 131-136.	8.7	288
93	Sweetness-dependent facilitation of sucrose drinking by raclopride is unrelated to calorie content. Pharmacology Biochemistry and Behavior, 1991, 40, 209-213.	2.9	46
94	Animal models as research tools in depression. International Journal of Geriatric Psychiatry, 1991, 6, 469-476.	2.7	2
95	8-OH-DPAT-induced place preference and place aversion: effects of PCPA and dopamine antagonists. Psychopharmacology, 1991, 103, 99-102.	3.1	50
96	An animal model of anhedonia: attenuation of sucrose consumption and place preference conditioning by chronic unpredictable mild stress. Psychopharmacology, 1991, 104, 255-259.	3.1	495
97	Suppression or facilitation of operant behaviour by raclopride dependent on concentration of sucrose reward. Psychopharmacology, 1991, 105, 239-246.	3.1	30
98	Voltammetric evidence that subsensitivity to reward following chronic mild stress is associated with increased release of mesolimbic dopamine. Psychopharmacology, 1991, 105, 275-282.	3.1	58
99	Reward-dependent suppression or facilitation of consummatory behaviour by raclopride. Psychopharmacology, 1991, 105, 355-360.	3.1	30
100	Time-, schedule-, and reinforcer-dependent effects of pimozide and amphetamine. Psychopharmacology, 1991, 104, 125-131.	3.1	27
101	Reversal of antidepressant action by dopamine antagonists in an animal model of depression. Psychopharmacology, 1991, 104, 491-495.	3.1	105
102	Changes in mesolimbic dopamine may explain stress-induced anhedonia. Cognitive, Affective and Behavioral Neuroscience, 1991, 19, 79-84.	1.3	58
103	Animal models for Clinical Psychopharmacology: Depression, Anxiety, Schizophrenia. International Review of Psychiatry, 1990, 2, 253-276.	2.8	19
104	The Role of Slow Changes in Catecholamine Receptor Function in The Action Of Antidepressant Drugs. International Review of Psychiatry, 1990, 2, 141-156.	2.8	4
105	Dopaminergic mechanism of imipramine action in an animal model of depression. Biological Psychiatry, 1990, 28, 223-230.	1.3	110
106	Attributional style and perceived stress in endogenous and reactive depression. Journal of Affective Disorders, 1990, 18, 281-287.	4.1	29
107	Effects of dopamine receptor antagonists on sucrose consumption and preference. Psychopharmacology, 1989, 99, 98-102.	3.1	86
108	Blockade of 8-OH-DPAT-induced feeding by dopamine antagonists. Psychopharmacology, 1989, 99, 402-408.	3.1	28

#	ARTICLE	IF	CITATIONS
109	Tests of functional equivalence between pimozide pretreatment, extinction and free feeding. Psychopharmacology, 1988, 95, 423-6.	3.1	23
110	Changes in dopamine autoreceptor sensitivity in an animal model of depression. Psychopharmacology, 1988, 94, 545-550.	3.1	71
111	Validation criteria for animal models of human mental disorders: Learned helplessness as a paradigm case. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1986, 10, 677-690.	4.8	297
112	Dopamine autoreceptors in the ventral tegmental area show subsensitivity following withdrawal from chronic antidepressant drug treatment. Psychopharmacology, 1986, 90, 64-71.	3.1	9
113	Conditioned taste aversion and conditioned drinking: Two independent and opposing effects of 5-hydroxytryptophan?. Psychopharmacology, 1986, 90, 79-84.	3.1	6
114	Apomorphine anorexia: The role of dopamine cell body autoreceptors. Psychopharmacology, 1986, 89, 65-8.	3.1	10
115	Antidepressants and serotonergic neurotransmission: An integrative review. Psychopharmacology, 1985, 85, 387-404.	3.1	175
116	The validity of animal models of depression. Psychopharmacology, 1984, 83, 1-16.	3.1	1,197
117	The neuropsychology of depression. Behavioral and Brain Sciences, 1984, 7, 746-747.	0.7	11
118	Animal Models of Depression: A Diathesis/Stress Approach. , 0, , 701-726.		12
119	Animal Models to Detect Antidepressants: Are New Strategies Necessary to Detect New Agents?. , 0, , 213-234.		5